These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 8061850)

  • 1. Spirapril: pharmacokinetic properties and drug interactions.
    Grass P; Gerbeau C; Kutz K
    Blood Press Suppl; 1994; 2():7-13. PubMed ID: 8061850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of spirapril in renal impairment.
    Meredith PA; Grass P; Guitard C; Elliott HL
    Blood Press Suppl; 1994; 2():14-9. PubMed ID: 8061840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of spirapril and spiraprilat in patients with chronic renal failure.
    Stein G; Sierakowski B; Grass P; Haufe CC; Jansa U; Weidinger G
    Blood Press Suppl; 1994; 2():47-53. PubMed ID: 8061846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and haemodynamic effects of a single oral dose of the novel ACE inhibitor spirapril in patients with chronic liver disease.
    Krähenbühl S; Grass P; Surve A; Kutz K; Reichen J
    Eur J Clin Pharmacol; 1993; 45(3):247-53. PubMed ID: 8276049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug interaction of spirapril hydrochloride monohydrate and hydrochlorothiazide. A clinical study to compare the pharmacokinetics after administration of spirapril hydrochloride monohydrate tablets, hydrochlorothiazide tablets and fixed combination bi-layer tablets.
    Schürer M; Erb K; Junge K; Schäfer HF; Schulz HU; Amschler S; Krupp S; Hermann R
    Arzneimittelforschung; 2003; 53(6):414-9. PubMed ID: 12872612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Kidney function in hypertensive patients with chronic renal failure treated with the dual eliminated ACE-inhibitor spirapril].
    Haufe CC; Sierakowski B; Jansa U; Stein G
    Med Klin (Munich); 1994 Aug; 89(8):416-20. PubMed ID: 7968874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension.
    Noble S; Sorkin EM
    Drugs; 1995 May; 49(5):750-66. PubMed ID: 7601014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous determination of spirapril and spiraprilat in plasma by capillary gas chromatography-mass spectrometry.
    Schürer M; Amschler S; Schulz HU; Schäfer HF
    Arzneimittelforschung; 2003; 53(5):307-13. PubMed ID: 12854357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic model relating spiraprilat plasma concentrations to systemic and regional hemodynamic effects in congestive heart failure.
    Bellissant E; Chau NP; Thuillez C; Gerbeau C; Richard C; Giudicelli JF
    J Cardiovasc Pharmacol; 1997 Aug; 30(2):253-60. PubMed ID: 9269955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of spirapril in mild-to-moderate hypertension.
    Hayduk K; Kraul H
    J Cardiovasc Pharmacol; 1999 Aug; 34 Suppl 1():S19-23. PubMed ID: 10499560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
    Perucca E; Cloyd J; Critchley D; Fuseau E
    Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical pharmacology of lisinopril.
    Case DE
    J Hum Hypertens; 1989 Jun; 3 Suppl 1():127-31. PubMed ID: 2550635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant administration of isradipine and spirapril prevents reduction of renal function induced by acute administration of spirapril in patients with reduced renal function.
    Wittenberg C; Erman A; Shohat J; Boner G
    Blood Press Suppl; 1994; 1():48-9. PubMed ID: 8205299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The acute hemodynamic, hormonal, and pharmacokinetic properties of oral spirapril in patients with moderate to severe heart failure.
    van den Broek SA; van Bruggen A; de Graeff PA; Hillege H; van Gilst WH; Wesseling H; Lie KI
    J Cardiovasc Pharmacol; 1991 Oct; 18(4):614-21. PubMed ID: 1724540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin converting enzyme inhibitors: spirapril and related compounds.
    Smith EM; Swiss GF; Neustadt BR; McNamara P; Gold EH; Sybertz EJ; Baum T
    J Med Chem; 1989 Jul; 32(7):1600-6. PubMed ID: 2544729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodynamic and cardiac effects of spiraprilat in normal and sodium depleted conscious dogs.
    Gérard JL; Pussard E; Berdeaux A; Giudicelli JF
    Fundam Clin Pharmacol; 1990; 4(5):547-58. PubMed ID: 2289746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized and double-blind comparison of isradipine and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure and hypertension.
    Petersen LJ; Petersen JR; Talleruphuus U; Møller ML; Ladefoged SD; Mehlsen J; Jensen HA
    Clin Nephrol; 2001 May; 55(5):375-83. PubMed ID: 11393383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity.
    Kharasch ED; Hoffer C; Walker A; Sheffels P
    Clin Pharmacol Ther; 2003 Mar; 73(3):199-208. PubMed ID: 12621385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amlodipine: pharmacokinetic profile of a low-clearance calcium antagonist.
    Abernethy DR
    J Cardiovasc Pharmacol; 1991; 17 Suppl 1():S4-7. PubMed ID: 16296697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insights on effect of kidney insufficiency on disposition of angiotensin-converting enzyme inhibitors: case of enalapril and benazepril in dogs.
    Toutain PL; Lefebvre HP; Laroute V
    J Pharmacol Exp Ther; 2000 Mar; 292(3):1094-103. PubMed ID: 10688628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.